Open AccessSetting of import tolerance for cyflufenamid in hops
Author(s) -
Anastassiadou Maria,
Bellisai Giulia,
Bernasconi Giovanni,
Brancato Alba,
Carrasco Cabrera Luis,
Ferreira Lucien,
Greco Luna,
Jarrah Samira,
Kazocina Aija,
Leuschner Renata,
Magrans Jose Oriol,
Miron Ileana,
Nave Stefanie,
Pedersen Ragnor,
Reich Hermine,
Santos Miguel,
Scarlato Alessia Pia,
Theobald Anne,
Vagenende Benedicte,
Verani Alessia
Publication year - 2021
Publication title -
efsa journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.076
H-Index - 97
ISSN - 1831-4732
DOI - 10.2903/j.efsa.2021.6492
Subject(s) - enforcement , agriculture , residue (chemistry) , business , risk assessment , food safety , microbiology and biotechnology , environmental health , medicine , computer science , political science , food science , law , computer security , biology , ecology , biochemistry
In accordance with Article 6 of Regulation ( EC ) No 396/2005, the applicant Nisso Chemical Europe GmbH submitted a request to the competent national authority in Greece to set an import tolerance for the active substance cyflufenamid in hops. The data submitted in support of the request were found to be sufficient to derive an maximum residue level ( MRL ) proposal for hops; however, further risk management considerations are required to decide on the appropriate MRL values considering that the MRL in the country of origin is lower than the MRL proposal derived from the residue trials. Adequate analytical methods for enforcement are available to control the residues of cyflufenamid in the crop under consideration at the validated limit of quantification ( LOQ ) of 0.01 mg/kg. Based on the consumer risk assessment results, EFSA concluded that the short‐term and long‐term intake of residues resulting from the use of cyflufenamid according to the reported agricultural practice in the country of origin is unlikely to present a risk to consumer health. This conclusion shall be regarded as indicative considering that some MRL proposals derived by EFSA during the MRL review require further confirmatory data.